ANAB
AnaptysBio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$56.80
−1.15%Year over year
Reported trailing growth
- Revenue
- +107.7%
- EBITDA
- +176.6%
- EBIT
- +140.7%
- EPS
- +82.2%
- Free cash flow
- +104.0%
- Operating cash flow
- +104.1%
Forward estimates
Based on analyst estimates
- Revenue
- -83.7%
- EBITDA
- +45.5%
- EPS
- +93.1%
Three-year CAGR
- Revenue
- +183.6%
- EBITDA
- +174.7%
- EBIT
- +141.7%
- Net income
- +90.9%
- EPS
- +91.0%
- Free cash flow
- +114.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026